ACTA试验中隐球菌脑膜炎不同抗真菌诱导方案的成本与生命年获益比较
基于ACTA随机试验,在马拉维、赞比亚、喀麦隆和坦桑尼亚比较五种隐球菌脑膜炎诱导方案的成本效果。结果显示,与2周AmB+5FC相比,1周AmB+5FC成本更低且更有效,2周口服FLU+5FC成本更低且效果相当;1周AmB+5FC相比口服FLU+5FC每挽救一个生命年的增量成本为208美元(95%CI 91-1210)。
要点
- 1周AmB+5FC较2周AmB+5FC成本更低且更有效。
- 2周口服FLU+5FC较2周AmB+5FC成本更低且效果相当。
- 1周AmB+5FC相比口服FLU+5FC每挽救生命年增量成本208美元。
核心结论
- 1周AmB联合5FC和2周口服FLU联合5FC均为具有成本效果的隐球菌脑膜炎诱导治疗方案。
研究设计与样本
- 基于ACTA随机试验的成本效果分析,参与者按2:1:1:1:1比例随机分配至五种诱导方案。
- 研究在马拉维、赞比亚、喀麦隆和坦桑尼亚开展,收集个体资源使用和健康结局数据。
- 成本效果以每挽救一个生命年的增量成本衡量,并进行非参数自举法分析。
主要发现
- 每患者总成本:2周口服FLU+5FC为1442美元,1周AmB+FLU为1763美元,1周AmB+5FC为1861美元,2周AmB+FLU为2125美元,2周AmB+5FC为2285美元。
- 与2周AmB+5FC相比,1周AmB+5FC成本更低且更有效,2周口服FLU+5FC成本更低且效果相当。
- 1周AmB+5FC相比口服FLU+5FC的增量成本效果比为每挽救生命年208美元(95%CI 91-1210)。
关键数值与推荐
- ACTA试验随机分组比例为2:1:1:1:1,对应五种诱导方案。
- 成本效果阈值为每挽救生命年的增量成本,1周AmB+5FC相比口服FLU+5FC为208美元(95%CI 91-1210)。
临床怎么用
- 在资源有限地区,可优先考虑1周AmB+5FC或2周口服FLU+5FC作为隐球菌脑膜炎诱导方案。
- 1周AmB+5FC相比口服FLU+5FC虽增量成本较低,但需结合当地药物可及性选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mortality from cryptoccocal meningitis remains high. The ACTA trial demonstrated that, compared with 2 weeks of amphotericin B (AmB) plus flucystosine (5FC), 1 week of AmB and 5FC was associated with lower mortality and 2 weeks of oral flucanozole (FLU) plus 5FC was non-inferior. Here, we assess the cost-effectiveness of these different treatment courses. METHODS: Participants were randomized in a ratio of 2:1:1:1:1 to 2 weeks of oral 5FC and FLU, 1 week of AmB and FLU, 1 week of AmB and 5FC, 2 weeks of AmB and FLU, or 2 weeks of AmB and 5FC in Malawi, Zambia, Cameroon, and Tanzania. Data on individual resource use and health outcomes were collected. Cost-effectiveness was measured as incremental costs per life-year saved, and non-parametric bootstrapping was done. RESULTS: Total costs per patient were US $1442 for 2 weeks of oral FLU and 5FC, $1763 for 1 week of AmB and FLU, $1861 for 1 week of AmB and 5FC, $2125 for 2 weeks of AmB and FLU, and $2285 for 2 weeks of AmB and 5FC. Compared to 2 weeks of AmB and 5FC, 1 week of AmB and 5FC was less costly and more effective and 2 weeks of oral FLU and 5FC was less costly and as effective. The incremental cost-effectiveness ratio for 1 week of AmB and 5FC versus oral FLU and 5FC was US $208 (95% confidence interval $91-1210) per life-year saved. CLINICAL TRIALS REGISTRATION: ISRCTN45035509. CONCLUSIONS: Both 1 week of AmB and 5FC and 2 weeks of Oral FLU and 5FC are cost-effective treatments.
引用
- Chen T, Mwenge L, Lakhi S, et al. Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. Clin Infect Dis. 2019. PMID: 30863852. doi:10.1093/cid/ciy971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。